Decitabine
Myelodysplastic Syndrome/Acute Myeloid Leukemia
National Cancer Institute (NCI)Small moleculePhase 2/3Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Myelodysplastic Syndrome/Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azacitidine City of Hope Medical Center | Phase 2/3 | BB |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 2/3 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2/3 | B |
Midostaurin National Cancer Institute (NCI) | Phase 2/3 | B |
Irinotecan National Cancer Institute (NCI) | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
Decitabine is also rated in:
acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →